Radionuclide therapy with samarium - oxabiphore, 153Sm in bone metastatic mamma and prostate carcinomas

Purpose. To study clinical potentialities of the radiopharmaceutical 153Sm-oxabiphore in palliative therapy of mamma and prostate carcinoma patients with bone metastases and pain syndrome. Material and Methods. 118 mamma carcinoma patients and 76 prostate carcinoma patients with multiple bone metastases and pain syndrome were given intravenous injections of samarium - oxabiphore, 153Sm. Activities in the range between 1,0 mCi and 1,5 mCi/kg body weight were used. Results. The peculiarities of the radiopharmaceutical distribution and accumulation in involved bone tissues were studied. Samarium - oxabiphore, 153Sm was found to be highly effective in palliative therapy for mamma and prostate carcinomas. In 93 (78,8 %) mamma carcinoma patients and in 60 (78,9 %) prostate carcinoma patients a stable relief of pain syndrome was achieved for 3 months and more. The quality of life (according to the Karnofsky scale) could be improved in both groups. Side effects of radionuclidе therapy are described.